210302-17-3
基本信息
CS-2890
BAM15 >=98% (HPLC)
N,N'-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine
[1,2,5]Oxadiazolo[3,4-b]pyrazine-5,6-diamine, N5,N6-bis(2-fluorophenyl)-
BAM 15 (N5,N6-bis(2-Fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine)
物理化学性质
| 沸点 | 421.7±55.0 °C(Predicted) |
| 密度 | 1.548±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | 溶于DMSO(35mg/ml) |
| 酸度系数(pKa) | -2.40±0.50(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| 稳定性 | 从购买之日起 2 年内保持稳定。 DMSO 溶液可在 -20°C 下保存长达 1 个月。 |
| InChI | InChI=1S/C16H10F2N6O/c17-9-5-1-3-7-11(9)19-13-14(20-12-8-4-2-6-10(12)18)22-16-15(21-13)23-25-24-16/h1-8H,(H,19,21,23)(H,20,22,24) |
| InChIKey | OEGJBRZAJRPPHL-UHFFFAOYSA-N |
| SMILES | C12=NON=C1N=C(NC1=CC=CC=C1F)C(NC1=CC=CC=C1F)=N2 |
安全数据
| 危险性符号(GHS) |    GHS07,GHS08,GHS09 |
| 警示词 | 危险 |
| 危险性描述 | H302-H361-H372-H410 |
| 防范说明 | P201-P264-P280-P301+P330+P331-P312 |
| WGK Germany | WGK 3 |
| 存储类别 | 11 - Combustible Solids |
| 危险性类别 | Aquatic Chronic 4 |
CS-2890价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-110284 | BAM 15 | 210302-17-3 | 1 mg | 340元 |
| 2026/09/15 | HY-110284 | CS-2890 BAM 15 | 210302-17-3 | 5mg | 750元 |
| 2026/09/15 | HY-110284 | CS-2890 BAM 15 | 210302-17-3 | 10mM * 1mLin DMSO | 825元 |
常见问题列表
| Target | Value |
|
AMPK
() |
BAM 15 is able to increase O 2 consumption across a broad dosing range without increasing ROS. BAM 15 and FCCP are structurally unrelated and it is observed that low doses of BAM 15 from 100 nM to 1 μM increase cellular O 2 consumption rate (OCR) to a similar degree as FCCP, but higher concentrations from 1 μM to 50 μM reveal that BAM 15 is able to maintain uncoupled respiration at a high rate in a range of cell lines. BAM 15 is fully capable of increasing mitochondrial respiration in the presence of oligomycin and does so across a broader concentration range than FCCP in both myoblasts and hepatocytes. BAM 15 induces mitochondrial swelling, demonstrating that BAM 15 is a protonophore. BAM15-treated cells are more viable than FCCP-treated cells when administered across a broad dosing range up to 50 μM.
Compare to vehicle-treated mice, animals that receive BAM 15 are protected from kidney injury as indicated by lower plasma creatinine levels at 24 and 48 h post-ischemia, reduced tubular necrosis, less depletion of brush border villi, less obstruction of proximal tubules, and less immune cell infiltration.